stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) EV/FCF
As of 6 November 2026, Kymera Therapeutics, Inc. (KYMR) trades at a EV/FCF of −42.4×. Over the past ten years it has ranged from −49.6× (August 2026) to 49.4× (September 2021); the current reading is higher than 4% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −24.4× | — |
| FY2024 | −12.2× | — |
| FY2023 | −8.1× | — |
| FY2022 | −6.0× | — |
| FY2021 | −20.0× | — |
| FY2020 | 9.9× | 363.30% |
| FY2019 | 2.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −44.4× | — |
| Mar 2026 | −30.6× | — |
| Dec 2025 | −24.4× | — |
| Sep 2025 | −19.3× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −77.9× |
| KYMR Kymera Therapeutics, Inc. | −40.2× |
| IBRX ImmunityBio, Inc. compare | −32.5× |
| SMMT Summit Therapeutics PLC compare | −23.1× |
| PCVX Vaxcyte, Inc. compare | −8.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 26.3× |
| TECH Bio-Techne Corp compare | 42.9× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
| TGTX TG Therapeutics, Inc. compare | 485× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement